Impaired endotoxin tolerance induction in patients with familial Mediterranean fever

Tigran K Davtyan1, Gagik S Hakopyan, Samvel A Avetisyan

  • 1Laboratory of Immunology and Virology, Armenicum Research Center, Yerevan State Medical University, Republic of Armenia. tigdav@excite.com

Abstract

Insights

Familial Mediterranean Fever (FMF) involves periodic immune cell changes, with heightened endotoxin sensitivity during remission. Colchicine may restore normal immune responses in FMF patients.

Area of Science:

  • Immunology
  • Rheumatology
  • Genetics

Background:

  • Familial Mediterranean Fever (FMF) is a chronic autoinflammatory disorder characterized by recurrent febrile attacks.
  • Neutrophil and monocyte activation are key components of the inflammatory response in FMF.

Purpose of the Study:

  • To investigate periodic disturbances in proinflammatory activation of neutrophils and monocytes in FMF patients during attacks and remission.
  • To compare immune cell activation in FMF patients with Behçet's disease (BD) patients and healthy controls.

Main Methods:

  • Flow cytometry was used to assess phagocytosis, respiratory burst, CD11a/CD18 expression, and intracellular cytokine synthesis in 20 FMF patients and 10 BD patients.
  • Endotoxin tolerance induction was evaluated by measuring monocyte response to lipopolysaccharide (LPS) after initial exposure.

Main Results:

  • FMF patients showed increased neutrophil and monocyte phagocytic activity and oxidative burst during remission, and decreased activity during attacks.
  • Monocytes from FMF patients in remission failed to induce LPS tolerance, exhibiting heightened endotoxin sensitivity, unlike during attacks.
  • Colchicine treatment restored LPS tolerance induction in remission by increasing IL-4 synthesis in FMF patient monocytes.

Conclusions:

  • Chronic inflammation in FMF involves periodic immune cell activation changes and heightened endotoxin sensitivity, correlating with the disease's episodic nature.
  • Increased endotoxin sensitivity during remission may stem from a shift to 'classically' activated monocytes, impacting FMF treatment strategies.